MedPath

Interferon-Alpha Shows Promise in Reducing Myelofibrosis Risk and Mortality in Polycythemia Vera Patients

A recent study presented at the 2020 ASH Annual Meeting reveals that Interferon-alpha (IFN) significantly reduces the risk of myelofibrosis and improves overall survival in patients with polycythemia vera (PV), suggesting its potential as a long-term management strategy for both low- and high-risk PV patients.

Interferon-alpha (IFN) has been shown to delay and potentially prevent post-polycythemia vera (PV) myelofibrosis (MF) and improve survival rates among PV patients, according to findings from a single-center, retrospective study presented at the 2020 ASH Annual Meeting and Exposition. The study, led by Ghaith Abu-Zeinah, MD, highlighted that IFN reduces the risk of myelofibrosis by 9% per year and decreases overall mortality by 6% per year, independent of age, sex, thrombosis history, cardiovascular risk factors, or other treatments.
Key Findings:
  • Myelofibrosis Risk Reduction: IFN treatment was associated with a significant reduction in the risk of developing myelofibrosis.
  • Survival Improvement: Patients treated with IFN showed improved overall survival, especially in high-risk PV cases.
  • Bone Marrow Response: In some patients, IFN treatment led to complete bone marrow responses, with bone marrow fibrosis being reversed.
The study analyzed data from 470 patients diagnosed with PV between 1966 and 2019, focusing on those treated with IFN, hydroxyurea (HU), or phlebotomy only. High-risk PV patients treated with IFN had a 20-year overall survival probability of 66%, compared to 40% in the HU group and 14% in the phlebotomy-only group. For low-risk patients, the myelofibrosis-free survival rate was significantly higher in the IFN group (84%) compared to the HU (65%) and phlebotomy-only (55%) groups.
Clinical Implications:
  • The findings suggest that IFN could be considered as a long-term management strategy for low-risk PV patients and preferred over HU for high-risk patients, based on the study's data and ongoing clinical trials.
  • Current guidelines from the National Comprehensive Cancer Network and European LeukemiaNet recommend phlebotomy-only as initial treatment for low-risk patients and either HU or IFN for high-risk patients. However, this study advocates for a reconsideration of IFN's role in PV treatment strategies.
This research underscores the potential of IFN as a disease-modifying therapy in PV, addressing the unmet need for life-prolonging therapies in this patient population.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Flonoltinib and Selinexor Combinations Show Promise in Myelofibrosis Treatment

Flonoltinib demonstrated significant spleen and symptom response in myelofibrosis patients, suggesting it may be a new treatment option.
A phase 2 trial showed selinexor combined with ruxolitinib led to spleen length reduction and symptom alleviation in myelofibrosis patients previously treated with ruxolitinib.

Ruxolitinib Plus Pegylated Interferon Alfa-2a Shows Promise in Polycythemia Vera

Combination therapy with ruxolitinib and pegylated interferon alfa-2a demonstrates safety and efficacy in newly diagnosed polycythemia vera (PV) patients.
The COMBI II trial showed significant reductions in _JAK2_ V617F variant allele frequency and improvements in bone marrow cellularity and fibrosis.

Ruxolitinib Plus Peg-IFN Shows High Remission Rates in Polycythemia Vera

A phase 2 trial (COMBI II) reveals that ruxolitinib combined with pegylated-interferon-α2a (peg-IFN) induces high remission rates in newly diagnosed polycythemia vera (PV) patients.
At 24 months, the overall remission rate was 56%, with 12% of patients achieving complete remission (CR), highlighting the potential of this combination therapy.

IMFINZI Regimen Demonstrates 25% Reduction in Death Risk in Bladder Cancer Trial

AstraZeneca's IMFINZI (durvalumab) combined with chemotherapy significantly improved event-free survival (EFS) and overall survival (OS) in the NIAGARA Phase III trial for muscle-invasive bladder cancer.
The IMFINZI perioperative regimen showed a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death compared to chemotherapy alone.

Ivonescimab Monotherapy Shows Significant PFS Improvement in NSCLC

Ivonescimab monotherapy reduced the risk of disease progression or death by 49% compared to pembrolizumab in PD-L1 positive advanced NSCLC patients.
The HARMONi-2 trial demonstrated a median progression-free survival of 11.14 months with ivonescimab versus 5.82 months with pembrolizumab.

FDA Approves Besremi, First Drug for Polycythemia Vera

The FDA has approved Besremi (ropeginterferon alfa-2b), an interferon drug by PharmaEssentia, as the first drug therapy specifically for polycythemia vera.
Besremi, administered as a bi-weekly subcutaneous injection, aims to reduce blood cell production by attaching to interferon alpha receptors in the bone marrow.

Real-World Use of Fedratinib for Myelofibrosis Following Ruxolitinib Failure

A study on the real-world application of fedratinib for myelofibrosis patients after ruxolitinib failure shows significant spleen size reduction and symptom improvement.

Ropeginterferon Alfa-2b: Optimized Dosing Strategies Show Promise in Myeloproliferative Neoplasms

Ropeginterferon alfa-2b is approved for polycythemia vera (PV), with ongoing studies exploring optimized dosing for improved outcomes.
Clinical trials suggest a 250-350-500 mcg regimen may lead to faster hematological remission compared to the standard lower-dose titration.

Advances in Prognostication and Treatment of Polycythemia Vera with Pegylated Interferon and MDM2 Inhibition

Recent studies highlight the efficacy of pegylated interferon (IFN) and MDM2 inhibition in treating Polycythemia Vera (PV), a type of myeloproliferative neoplasm. Pegylated IFN, particularly IFN-α, shows promise in normalizing blood counts, reducing phlebotomy needs, and potentially inducing molecular remissions. Despite its benefits, IFN's side effects limit its use. MDM2 inhibitors, targeting the TP53 pathway, offer a novel approach, with clinical trials demonstrating reduced JAK2V617F allele burdens and improved patient outcomes. These advancements underscore the evolving landscape of PV treatment, emphasizing the need for further research to optimize therapeutic strategies.

Ropeginterferon Alfa-2b Shows Promise in Polycythemia Vera Treatment

Ropeginterferon alfa-2b demonstrates a high overall response rate of 90% in polycythemia vera (PV) patients, including complete and partial hematologic responses.
The study found no dose-limiting toxicities with ropeginterferon alfa-2b, supporting its favorable safety profile and potential for long-term use.

Reference News

[1]
Interferon-Alpha Reduces Myelofibrosis Risk, Mortality ...
onclive.com · Dec 21, 2020

Interferon-alpha (IFN) treatment in polycythemia vera (PV) patients reduces myelofibrosis risk by 9% and overall mortali...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy